Progress in the application of rituximab in treating primary mediastinal B-cell lymphoma
10.3760/cma.j.issn.1004-4221.2017.05.023
- VernacularTitle:利妥昔单抗应用于临床后原发纵隔B细胞淋巴瘤治疗进展
- Author:
Liming XU
;
Yajing YUAN
;
Peiguo WANG
;
Gang WU
- Keywords:
B-cell lymphoma/rituximab;
B-cell lymphoma/radiotherapy;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2017;26(5):582-587
- CountryChina
- Language:Chinese
-
Abstract:
Primary mediastinal large B-cell lymphoma (PMBCL) is morphologically similar to diffuse large B-cell lymphoma (DLBCL) and nodular sclerosis Hodgkin lymphoma.For most PMBCL patients, chemotherapy plus consolidation radiotherapy showed that the latter could improve PMBCL responsiveness and progression-free survival (PFS), and its combined use with chemotherapy demonstrated higher therapeutic efficacy.Recent clinical studies suggested that rituximab and anthracycline chemotherapy regimens could increase PMBCL treatment efficacy, reduce early treatment failure, enhance PFS and overall survival, and improve prognosis.Although rituximab combined with some high-intensity chemotherapy without radiotherapy have achieved good results, many studies still support the use of post-immunochemotherapy consolidation mediastinal radiotherapy.Based on the results of a few studies with a small sample size, patients who were assessed as complete metabolic remission by PET following high-intensity immunochemotherapy may omit consolidation radiotherapy.However, these results will need to be further confirmed by large-sample multicenter clinical trials.Consolidation radiotherapy is recommended for patients with poor prognostic factors or PET score>3.
